Akeso
162
46
68
57
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
4.9%
8 terminated/withdrawn out of 162 trials
87.7%
+1.1% vs industry average
22%
36 trials in Phase 3/4
0%
0 of 57 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (162)
Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma
Role: lead
A Study of AK157D1 for Injection in Advanced Solid Tumors
Role: lead
AK104 for Recurrent or Metastatic Vulvar Cancer
Role: lead
A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Chronic Rhinosinusitis With Nasal Polyps
Role: lead
SCRT Followed by AK112 in pMMR/MSS Mid-low Rectal Cancer
Role: collaborator
A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Small Cell Lung Cancer
Role: lead
AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC
Role: lead
Phase III Study of AK112 for NSCLC Patients
Role: collaborator
A Phase II Study of AK146D1 Combined With AK112 in Advanced Breast Cancer
Role: lead
A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer
Role: lead
A Study of AK104 Monotherapy or AK104 Plus Axitinib in Advanced/Metastatic Renal Cell Carcinoma
Role: lead
A Study Evaluating the Single Subcutaneous Injection of Ebronucimab in Healthy Male Chinese Subjects
Role: lead
A Phase Ib/II Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced Malignant Tumors
Role: lead
A Phase II Trial of AK104 in Advanced Non-Small Cell Lung Cancer
Role: lead
A Phase II Study of AK146D1 Mono or Combined With AK112 in Advanced Urothelial Carcinoma
Role: lead
Anlotinib+Cadonilimab+PULSAR in Advanced Biliary Tract Cancer
Role: collaborator
A Study to Evaluate the PK Similarity of AK104 in Healthy Chinese Male Participations
Role: lead
A Phase I Clinical Study of AK150 in Advanced Malignant Solid Tumor
Role: lead
A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Breast Cancer
Role: lead
A Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors
Role: lead